Inhaled nitric oxide in neonatal and pediatric acute respiratory distress syndrome
- 1 November 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 24 (11) , 1913-1919
- https://doi.org/10.1097/00003246-199611000-00024
Abstract
Inhaled nitric oxide is a potent and selective pulmonary artery vasodilator. We studied the effects of nitric oxide inhalation in neonatal and pediatric acute respiratory distress syndrome (ARDS) patients with respect to dosage, prolonged inhalation, and weaning. Prospective, open-label study. Neonatal and pediatric intensive care units of a level three university hospital. Seventeen patients with severe ARDS (1 day to 6 yrs of age [mean 1.75]; oxygenation index of >20 cm H2 O/torr) were enrolled. To identify the optimal dosage for continuous nitric oxide inhalation, doses between 1 and 80 parts per million (ppm) of nitric oxide were tested after the patients had stabilized. Daily withdrawals of nitric oxide were made, according to predetermined criteria. Nine neonatal and eight pediatric ARDS patients (mean Pediatric Risk of Mortality score 28.4 +/- 6.1; mortality risk 54 +/- 15%) were studied. The following variables changed within 24 hrs of nitric oxide inhalation: mean oxygenation index decreased by 56% (from 34 +/- 12 to 15 +/- 7 cm H2 O/torr, p = .0004); alveolar-arterial O2 gradient decreased by 31% (from 579 +/- 71 to 399 +/- 102 torr (77.2 +/- 9.5 to 53.2 +/- 13.6 kPa), p = .0004); and mean systemic arterial pressure increased by 15% (from 49 +/- 10 to 57 +/- 12 mm Hg, p = .0029). The optimal dose of nitric oxide was 20 ppm in neonates (with additional persistent pulmonary hypertension of the newborn) and 10 ppm in pediatric patients. Prolonged inhalation (4 to 21 days) was associated with continuous improvement of oxygenation. An oxygenation index of <5 cm H2 O/torr predicted successful withdrawal, with a sensitivity of 75% and a specificity of 89%. None of the patients had to be rescued with extracorporeal membrane oxygenation and 16 of the 17 patients survived. Inhaled nitric oxide enhances pulmonary gas exchange, with concomitant hemodynamic stabilization, in neonatal and pediatric ARDS. Best effective doses were 10 ppm of nitric oxide in pediatric ARDS and 20 ppm in neonates. Treatment should be continued until an oxygenation index of <or=to5 cm H2 O/torr is achieved. Effects on outcome need verification in larger controlled trials.Keywords
This publication has 28 references indexed in Scilit:
- Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failureThe Journal of Pediatrics, 1994
- Sepsis terminology in pediatricsThe Journal of Pediatrics, 1994
- Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxideThe Journal of Pediatrics, 1993
- Inhaled Nitric Oxide for the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1993
- Adult respiratory distress syndrome in pediatric patients. II. ManagementThe Journal of Pediatrics, 1988
- Adult respiratory distress syndrome in pediatric patients. I. Clinical aspects, pathophysiology, pathology, and mechanisms of lung injuryThe Journal of Pediatrics, 1988
- Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unitThe Journal of Pediatrics, 1987
- Cardiopulmonary abnormalities in severe acute respiratory failureThe Journal of Pediatrics, 1984
- Persistent pulmonary hypertension in the neonate: Diagnosis and managementThe Journal of Pediatrics, 1983
- Cardiovascular management in acute hypoxemic respiratory failureThe American Journal of Cardiology, 1981